4. BioTime (BTIM)
Company Profile: BioTime is engaged in the business of developing blood plasma volume expanders and related products and stem-cell-related products, and technology for diagnostic, therapeutic and research use.
Altman Z-score: 55.66Closing Price: $4.65 (Sept. 15) Financial Metrics: BioTime has a price-to-book ratio of 7.22, which suggests the stock may be overvalued based on book value. BioTime's quick ratio, which measures the ability to meet short-term obligations with its most liquid assets, is a whopping 13, indicating the company would have no trouble meeting its current liabilities. Analyst Consensus: No analyst has coverage on BioTime.